Medigen Vaccine Biologics Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Medigen Vaccine Biologics heeft een totaal eigen vermogen van NT$3.8B en een totale schuld van NT$22.9M, wat de schuld-eigenvermogensverhouding op 0.6% brengt. De totale activa en totale passiva bedragen respectievelijk NT$4.3B en NT$460.5M.

Belangrijke informatie

0.6%

Verhouding schuld/eigen vermogen

NT$22.95m

Schuld

Rente dekkingsratio	n/a
Contant	NT$1.78b
Aandelen	NT$3.85b
Totaal verplichtingen	NT$460.55m
Totaal activa	NT$4.31b

Recente financiële gezondheidsupdates

We're Hopeful That Medigen Vaccine Biologics (GTSM:6547) Will Use Its Cash Wisely

Mar 31

Would Medigen Vaccine Biologics (GTSM:6547) Be Better Off With Less Debt?

Dec 15

Recent updates

We're Hopeful That Medigen Vaccine Biologics (GTSM:6547) Will Use Its Cash Wisely

Mar 31

Would Medigen Vaccine Biologics (GTSM:6547) Be Better Off With Less Debt?

Dec 15

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( NT$2.5B ) 6547 } overtreffen de korte termijn passiva ( NT$210.0M ).

Langlopende schulden: De kortetermijnactiva 6547 ( NT$2.5B ) overtreffen de langetermijnschulden ( NT$250.5M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 6547 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 6547 is de afgelopen 5 jaar gedaald van 35.9% naar 0.6%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: 6547 heeft op basis van de huidige vrije kasstroom voldoende cash runway voor meer dan 3 jaar.

Voorspelling contante baan: 6547 heeft voldoende kasruimte voor meer dan 3 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 4.7 % per jaar.

Medigen Vaccine Biologics Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

We're Hopeful That Medigen Vaccine Biologics (GTSM:6547) Will Use Its Cash Wisely

Would Medigen Vaccine Biologics (GTSM:6547) Be Better Off With Less Debt?

Recent updates

Medigen Vaccine Biologics Corporation to Report Q3, 2024 Results on Nov 04, 2024

Medigen Vaccine Biologics Corporation to Report Q2, 2024 Results on Aug 01, 2024

Less than half of directors are independent

Medigen Vaccine Biologics Corporation to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings released: NT$3.53 loss per share (vs NT$4.56 loss in FY 2022)

Medigen Vaccine Biologics Corporation, Annual General Meeting, Jun 13, 2024

First half 2023 earnings released: NT$1.61 loss per share (vs NT$1.41 loss in 1H 2022)

Medigen Vaccine Biologics Corporation Withdraws Covid-19 Vaccine Provisional Application and Update with Three-Dose Data for Further Review

Medigen Vaccine Biologics Corporation Approves the Election of Ming-Yi ,Wu as Independent Director and Member of Audit and Remuneration Committees

Medigen Vaccine Biologics Corporation Files New Drug Application of MVC EV71 Vaccine (Envacgen) to Drug Administration of Vietnam

Less than half of directors are independent

Less than half of directors are independent

Medigen Vaccine Biologics Corporation Announces Results of MVC COVID-19 Vaccine Phase 3 Clinical Trial in Thailand

Third quarter 2022 earnings released: NT$0.95 loss per share (vs NT$2.16 profit in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: NT$0.97 loss per share (vs NT$0.57 loss in 2Q 2021)

Now 20% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Now 20% undervalued after recent price drop

MVC File Provisional Approval Application of COVID-19 Vaccine to Therapeutic Goods Administration

First quarter 2022 earnings released: NT$0.66 loss per share (vs NT$0.74 loss in 1Q 2021)

Medigen Vaccine Biologics Corporation Announces Update on Clinical Development on MVC Covid-19 Vaccine

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Bluewillow Biologics and Medigen Vaccine Biologics Announce Positive Results for Intranasal Covid-19 Booster Candidate in Pre-Clinical Studies

Medigen Vaccine Biologics Corporation Files New Drug Application (NDA) of MVC Quadrivalent Influenza Vaccine to Taiwan Food and Drug Administration

Third quarter 2021 earnings released: EPS NT$3.20 (vs NT$0.98 loss in 3Q 2020)

Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation Announces Launch of Its Covid-19 Vaccine Mvc-Cov1901 Adjuvanted with Dynavax's Cpg 1018 Adjuvant

Second quarter 2021 earnings released: NT$0.84 loss per share (vs NT$0.93 loss in 2Q 2020)

First quarter 2021 earnings released: NT$0.74 loss per share (vs NT$0.75 loss in 1Q 2020)

We're Hopeful That Medigen Vaccine Biologics (GTSM:6547) Will Use Its Cash Wisely

New 90-day high: NT$112

Medigen Vaccine Biologics Corporation Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax's CpG 1018 Announces First Participant Dosed in Phase 2 Clinical Trial in Taiwan

Metronic Global Berhad Provides Update on Termination of MOA with Medigen Vaccine Biologics Corporation to Obtain Exclusive Distribution Rights for MVC’s COVID-19 Vaccine

New 90-day high: NT$110

Would Medigen Vaccine Biologics (GTSM:6547) Be Better Off With Less Debt?

New 90-day high: NT$107

Metronic Global Berhad Announces Memorandum of Agreement with Medigen Vaccine Biologics Corporation

Medigen Vaccine Biologics Corporation and BlueWillow Biologics, Inc. Partners to Develop Intranasal Vaccine for SARS-CoV-2

Medigen Vaccine Biologics Corporation COVID-19 Vaccine Combined with Dynavax Technologies Corporation CpG 1018 Adjuvant Receives Taiwan Government Subsidy with First Participant Dosed in Early October

New 90-day low: NT$89.40

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven